Print

AVEG 022A

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adults

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) July 10, 1996
ALVAC-HIV MN120TMG strain (vCP205),rgp120/HIV-1 SF-2 Canarypox Env gp120, TM gp41, gag, protease B MN/LAI; Protein Env gp120 B SF-2
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
rgp120/HIV-1 SF-2 Protein
USA 150
NCT00000847
http://www.clinicaltrials.gov/ct2/show/NCT00000847